Skip to main content

Advertisement

SpringerLink
Log in

Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Whether the preoperative use of somatostatin analogues (SA) improves surgical outcomes in acromegaly is still a matter of debate.

Objective

We conducted a systematic review of randomized, controlled trials that compared the short-term outcomes of preoperative use of SA (Pre-SA) with direct TSS (No-SA) for the treatment of newly diagnosed acromegaly.

Methods

Embase, Pubmed, Lilacs, and Central Cochrane were used as our data sources. The primary outcomes were no need for any adjuvant treatment 3 months after surgery, based on biochemical results (GH nadir after OGTT <1 μg/L and normal IGF-1 for age and gender), quality of life and mortality. The included trials were analyzed using the Grading of Recommendations Assessment, Development, and Evaluation approach.

Results

A total of 2.099 references were identified and two reviewers independently screened the titles and abstracts. From the 14 potentially eligible studies, four were included and ten were excluded due to lack of randomization or different outcomes. A pool of 261 patients was randomly assigned to Pre-SA or No-SA. Meta-analysis of IGF1 normalization showed a significant difference in favor of Pre-SA (RR 2.47; 95 % CI 1.66, 3.77). Adding a GH nadir on OGTT ≤1 μg/L, we found a RR of 2.15 (95 % CI 1.39, 3.33). Quality of evidence for no need of adjuvant postoperative treatment was moderate, but for improving quality of life was very low and for mortality was absent.

Conclusion

Pre-SA increases the chance of biochemical control of acromegaly 3 months after TSS in patients harboring GH-secreting pituitary macroadenomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Melmed S, Colao A, Barkan A et al (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509–1517. doi:10.1210/jc.2008-2421

    Article  CAS  PubMed  Google Scholar 

  2. Melmed S (2006) Acromegaly. N Engl J Med 355:2558–2573. doi:10.1111/j.1365-2036.2011.04905.x

    Article  CAS  PubMed  Google Scholar 

  3. Vieira Neto L, Abucham J, de Araujo LA et al (2011) Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol 55:91–105. doi:10.1590/S0004-27302011000200001

    Article  PubMed  Google Scholar 

  4. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur J Endocrinol 152:379–387. doi:10.1530/eje.1.01863

    Article  CAS  PubMed  Google Scholar 

  5. Wass JA, Turner HE, Adams CB, HE, Adams CB (1999) The importance of locating a good pituitary surgeon. Pituitary 2:51–54

    Article  CAS  PubMed  Google Scholar 

  6. Stevenaert A, Harris AG, Kovacs K, Beckers A (1992) Presurgical octreotide treatment in acromegaly. Metabolism 51–58

  7. Abe T, Lüdecke DK (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145:137–145. doi:10.1530/eje.0.1450137

    Article  CAS  PubMed  Google Scholar 

  8. Colao A, Ferone D, Cappabianca P et al (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308–3314. doi:10.1097/00019616-199803000-00020

    Article  CAS  PubMed  Google Scholar 

  9. Barkan AL, Lloyd RV, Chandler WF et al (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67:1040–1048

    Article  CAS  PubMed  Google Scholar 

  10. Biermasz NR, van Dulken H, Roelfsema F (1999) Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84:3551–3555

    Article  CAS  PubMed  Google Scholar 

  11. Kristof RA, Stoffel-Wagner B, Klingmüller D, Schramm J (1999) Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141:399–405. doi:10.1007/s007010050316

    Article  CAS  Google Scholar 

  12. The Cochrane Collaboration (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Version 510 [updated March 2011] Cochrane Collab. www.cochrane-handbook.org

  13. Guyatt GH, Oxman AD, Kunz R et al (2008) What is “quality of evidence” and why is it important to clinicians? BMJ Br Med J 336:995–998. doi:10.1136/bmj.39490.551019.BE

    Article  Google Scholar 

  14. Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394. doi:10.1016/j.jclinepi.2010.04.026

    Article  PubMed  Google Scholar 

  15. Carlsen SM, Lund-Johansen M, Schreiner T et al (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93:2984–2990. doi:10.1210/jc.2008-0315

    Article  CAS  PubMed  Google Scholar 

  16. Shen M, Shou X, Wang Y et al (2010) Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J 57:1035–1044. doi:10.1507/endocrj.K10E-203

    Article  PubMed  Google Scholar 

  17. Mao Z, Zhu Y, Tang H et al (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 162:661–666. doi:10.1530/EJE-09-0908

    Article  CAS  PubMed  Google Scholar 

  18. Li Z-Q, Quan Z, Tian H-L, Cheng M (2012) Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. J Int Med Res 40:517–524. doi:10.1177/147323001204000213

    Article  CAS  PubMed  Google Scholar 

  19. Carlsen SM, Svartberg J, Schreiner T et al (2011) Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin Endocrinol (Oxf) 74:736–743. doi:10.1111/j.1365-2265.2011.03982.x

    Article  CAS  Google Scholar 

  20. Losa M, Mortini P, Urbaz L et al (2006) Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 104:899–906. doi:10.3171/jns.2006.104.6.899

    Article  CAS  PubMed  Google Scholar 

  21. Plöckinger U, Quabbe H-J (2005) Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 147:485–493; discussion 493. doi:10.1007/s00701-005-0511-9

  22. Waśko R, Ruchała M, Sawicka J et al (2000) Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J Endocrinol Invest 23:12–18

    Article  PubMed  Google Scholar 

  23. Ezzat S, Kontogeorgos G, Redelmeier DA et al (1995) In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 133:686–690. doi:10.1530/eje.0.1330686

    Article  CAS  PubMed  Google Scholar 

  24. Thapar K, Kovacs KT, Stefaneanu L et al (1997) Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin Proc 72:893–900. doi:10.4065/72.10.893

    CAS  PubMed  Google Scholar 

  25. Cannavò S, Squadrito S, Curtò L et al (2001) Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm Metab Res 33:618–624. doi:10.1055/s-2001-17910

    Article  PubMed  Google Scholar 

  26. Giustina A, Chanson P, Kleinberg D et al (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10:243–248. doi:10.1038/nrendo.2014.21

    Article  CAS  PubMed  Google Scholar 

  27. Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S et al (2013) Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. doi:10.1371/journal.pone.0061523

    PubMed Central  PubMed  Google Scholar 

  28. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol 64:1294–1302. doi:10.1016/j.jclinepi.2011.03.017

    Article  PubMed  Google Scholar 

  29. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol 64:1303–1310. doi:10.1016/j.jclinepi.2011.04.014

    Article  PubMed  Google Scholar 

  30. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 64:1283–1293. doi:10.1016/j.jclinepi.2011.01.012

    Article  PubMed  Google Scholar 

  31. Guyatt GH, Oxman AD, Montori V et al (2011) GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol 64:1277–1282. doi:10.1016/j.jclinepi.2011.01.011

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Gordon H. Guyatt to help us to apply the GRADE system in this Systematic Review and Dr. Sergio Alberto Rupp de Paiva to motivate us to use the GRADE approach. This work was supported by Sao Paulo State Research Foundation (FAPESP); Grant # 2011/20517-2.

Conflict of interest

V. S. Nunes and C. L. Boguszewski receive consulting fees from Novartis and travel expenses from Ipsen. J. M. S. Correa, M. E. S. Puga and E. M. K. Silva have no relationships to disclose.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University/UNESP, Sao Paulo, Brazil

    V. S. Nunes & J. M. S. Correa

  2. Brazilian Cochrane Centre - Discipline of Emergency Medicine and Evidence-Based Medicine, Federal University of Sao Paulo (UNIFESP), São Paulo, Brazil

    M. E. S. Puga & E. M. K. Silva

  3. Department of Internal Medicine, Endocrine Division (SEMPR), Federal University of Parana, Curitiba, Brazil

    C. L. Boguszewski

Authors
  1. V. S. Nunes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. S. Correa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. E. S. Puga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. M. K. Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. L. Boguszewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. S. Nunes.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nunes, V.S., Correa, J.M.S., Puga, M.E.S. et al. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary 18, 500–508 (2015). https://doi.org/10.1007/s11102-014-0602-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-014-0602-9

Keywords

Search

Navigation